Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000062057

Apexbio Technology LLC Rifabutin 72559-06-9 100mg
SDP

Catalog No. 5000062057
Encompass_Preferred

Rifabutin is an antimycobacterial agent derived from rifamycin S belonging to the ansamycin antibiotic class It acts by binding to bacterial RNA polymerase inhibiting RNA synthesis and thus suppressing mycobacterial replication Rifabutin exhibits inhibitory activity against Mycobacterium tuberculosis strains with reported minimum inhibitory concentrations (MICs) typically ranging between 0 125 and 0 25 g/ml Due to its bacterial membrane affinity mediated through electrostatic interactions with phospholipid headgroups Rifabutin has attracted research interest in tuberculosis treatment models Experimentally its administration in murine tuberculosis infection models reduced bacterial load in lung liver and spleen tissues It is additionally investigated in clinical contexts particularly to manage tuberculosis infections in immunocompromised hosts including organ transplant recipients

Catalog No. 50-000-62057 Supplier Apexbio Technology LLC Supplier No. B2126100
May include imposed supplier surcharges.
Add to Cart
Add to Cart

Rifabutin is an antimycobacterial agent derived from rifamycin S belonging to the ansamycin antibiotic class It acts by binding to bacterial RNA polymerase inhibiting RNA synthesis and thus suppressing mycobacterial replication Rifabutin exhibits inhibitory activity against Mycobacterium tuberculosis strains with reported minimum inhibitory concentrations (MICs) typically ranging between 0 125 and 0 25 g/ml Due to its bacterial membrane affinity mediated through electrostatic interactions with phospholipid headgroups Rifabutin has attracted research interest in tuberculosis treatment models Experimentally its administration in murine tuberculosis infection models reduced bacterial load in lung liver and spleen tissues It is additionally investigated in clinical contexts particularly to manage tuberculosis infections in immunocompromised hosts including organ transplant recipients

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.